Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing lansoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* (*H. pylori*) infection.
## Primary Indications
* Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
* **Sompraz HP:** One blister pack (containing lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg) taken orally twice daily for 7 to 14 days.
* *Note:* The amoxicillin component is 1000 mg twice daily, and clarithromycin is 500 mg twice daily. Lansoprazole is 30 mg twice daily.
## Pediatric Dosing
* Dosing in pediatric patients has not been established for this specific combination product. Individual components have pediatric dosing recommendations that would need to be considered if used off-label or in different formulations.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is recommended for lansoprazole. For amoxicillin and clarithromycin, dose reduction may be necessary in severe renal impairment (CrCl < 30 mL/min).
* **Hepatic Impairment:** Use lansoprazole with caution. Clarithromycin dose reduction may be considered in moderate to severe hepatic impairment.
## Contraindications
* Hypersensitivity to lansoprazole, amoxicillin, clarithromycin, or other macrolides or penicillins.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Concomitant use with rifabutin, cisapride, pimozide, or astemizole.
* Severe renal impairment in combination with moderate hepatic impairment for clarithromycin.
## Adverse Effects
* **Common:** Diarrhea, nausea, abdominal pain, taste disturbance, headache, rash.
* **Serious:** *Clostridium difficile*-associated diarrhea (CDAD), anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic dysfunction, QT prolongation (clarithromycin), tendon rupture (fluoroquinolones, though not in this product, important to consider for bacterial resistance discussions).
## Key Drug Interactions
* **Lansoprazole:** May decrease the absorption of drugs requiring an acidic environment (e.g., ketoconazole, itraconazole, iron salts). May increase levels of drugs metabolized by CYP3A4.
* **Clarithromycin:** Potent inhibitor of CYP3A4. Significantly increases serum concentrations of numerous drugs (e.g., statins, warfarin, carbamazepine, theophylline, cyclosporine, tacrolimus, simvastatin, atorvastatin, colchicine). Avoid concomitant use with cisapride, pimozide, astemizole, ergotamine, and dihydroergotamine.
* **Amoxicillin:** May decrease the effectiveness of oral contraceptives. May interact with allopurinol (increased rash risk).
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for diarrhea and signs of *C. difficile* infection.
* Monitor liver function tests, especially with prolonged therapy or in patients with hepatic impairment.
* Assess for therapeutic response (eradication of *H. pylori*).
## Clinical Pearls
* Administer the combination product as a single blister pack to ensure correct dosing.
* The full 7- to 14-day course of therapy should be completed to ensure eradication of *H. pylori* and prevent resistance.
* Consider resistance rates of *H. pylori* to clarithromycin in the local geographic area, as this can impact efficacy.
* Advise patients to report any severe or persistent diarrhea, rash, or signs of allergic reaction immediately.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete and up-to-date details before making treatment decisions.*
